ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022
Restoring vision using optogenetics without being blind to the risks.
Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)
A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- A Systematic Review of Optogenetic Vision Restoration: History, Challenges, and New Inventions from Bench to Bedside.Cold Spring Harbor perspectives in medicine · 2023Pooled it
- Restoration of Saccadic Eye Movements and Visually Guided Behavior in Ambient White Light with Photoswitchable Small Molecules.Journal of the American Chemical Society · 2026Article
- Control of cortical population activity with patterned microstimulation.bioRxiv : the preprint server for biology · 2026Article
- Genetic manipulation technologies for precise cellular control: a comparative review of five approaches.Frontiers in bioengineering and biotechnology · 2026Review
- How and where Effectively Apply Cerebellum Stimulation: The frequency-dependent Modulation of Cerebellar Output by Transcranial Alternating Current Stimulation.Cerebellum (London, England) · 2025Article
- Regulatory aspects of optogenetic research and therapy for retinitis pigmentosa under EU law.Frontiers in medical technology · 2025Review
- Retinitis Pigmentosa and Therapeutic Approaches: A Systematic Review.Journal of clinical medicine · 2024Review
- Tetherless Optical Neuromodulation: Wavelength from Orange-red to Mid-infrared.Neuroscience bulletin · 2024Review
- Nanoparticle-based optical interfaces for retinal neuromodulation: a review.Frontiers in cellular neuroscience · 2024Review
- Article
- The thin line between seeing risks and venturing scientific progress.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Light-induced charge generation in polymeric nanoparticles restores vision in advanced-stage retinitis pigmentosa rats.Nature communications · 2022Article
- A narrative review of cortical visual prosthesis systems: the latest progress and significance of nanotechnology for the future.Annals of translational medicine · 2022Review
- Current perspective on retinal remodeling: Implications for therapeutics.Frontiers in neuroanatomy · 2022Article
- The Roles of Optogenetics and Technology in Neurobiology: A Review.Frontiers in aging neuroscience · 2022Review
- Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention.Frontiers in integrative neuroscience · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinit is pigmentosa is an incurable degenerative disease that causes loss of light-sensitive cells in the retina and leads to severe vision impairment. The development of optogenetics has created great hype around its potential to treat retinitis pigmentosa by the introduction of light-sensitive proteins into other neural cells in the retina. The first-in-human studies of optogenetic treatment for this disease have recently been reported (NCT02556736 and NCT03326336). The treatment involves irreversible gene therapy and requires access to specially designed goggles to deliver light to the treated eye. These highly innovative and high-profile clinical trials raise numerous ethical issues that must be addressed during the early phases of research and clinical testing to ensure trial participants are treated fairly and can provide appropriate informed consent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.